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Growth and metastasis of solid neoplasms require the
recruitment of a supporting tumor stroma. A highly
consistent trait of tumor stromal ¢broblasts in most
epithelial cancers is the induction of ¢broblast activa-
tion protein (FAP), a member of the serine protease fa-
mily. Recently it was demonstrated that FAP has both
dipeptidyl peptidase and collagenolytic activity capable
of degrading gelatin and type I collagen. In this study,
we describe the expression and enzyme activity of
FAP in benign and malignant melanocytic skin tumors.
FAP-positive ¢broblasts were detected immunohisto-
chemically in the reactive stroma of all melanocytic
nevi tested. In primary and metastatic melanomas an
upregulation of FAP expression in the reactive me-
senchyme could be observed.Whereas 30% of the nevi
revealed additional FAP expression on subsets of
melanocytic cells, melanoma cells from primary and
metastatic melanomas were FAP negative.This may in-
dicate a possible role for FAP in the control of tumor
cell growth and proliferation during melanoma carci-
nogenesis. Consistent with this in vivo expression pat-
tern FAP enzyme activity could be detected by a
speci¢c immunocapture assay in extracts of melanocy-
tic nevi and melanoma metastases, whereas no signi¢-
cant activity was detectable in normal adult skin.
Strong protein expression of FAP was observed in
patterned structures restricted to a subset of the mela-
noma metastases. Our ¢ndings that these FAP-positive
structures showed no overlap with endothelial cell sur-
face markers, nor with various melanoma antigens,
suggest that FAP is a marker for speci¢c stromal-cell-
derived patterns in cutaneous melanoma metastases.
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T
he invasive growth of solid tumors requires a num-
ber of cellular and molecular changes in the support-
ing stroma, including formation of lymphoid and
phagocytic in¢ltrates, release of peptide mediators
and proteolytic enzymes, and the production of an
altered extracellular matrix. The complex interplay between the
di¡erent cell types involved, including the malignant cells them-
selves, the endothelium, and tumor stroma ¢broblasts, is increas-
ingly understood (Ruiter et al, 2002). One key aspect of tumor
stroma formation in solid neoplasms is the production of new
blood vessels (angiogenesis) to provide an enhanced tumor blood
supply (Hanahan and Folkman, 1996). In addition, the supporting
stroma of most types of epithelial cancers contains an abundance
of specialized ¢broblasts, referred to as reactive tumor stromal ¢-
broblasts.Whereas tumor stromal ¢broblasts are not transformed,
they di¡er from resting ¢broblasts in normal adult tissues by a
characteristic gene expression pattern (Scanlan et al, 1994). A
highly consistent and speci¢c molecular trait of tumor stromal
¢broblasts in several types of epithelial cancers is the induction
of ¢broblast activation protein (FAP), a member of the serine
protease family (Garin-Chesa et al, 1990). FAP is an Mr 95,000 cell
surface protein, as detected by the monoclonal antibody F19
(Garin-Chesa et al, 1990). As a type II membrane-bound glyco-
protein, FAP shows close kinship to the heterodimeric partner di-
peptidyl peptidase IV (DPP-IV/CD26), which is widely expressed
in normal tissues with roles in T cell costimulation, chemokine
biology, type II diabetes, and tumorigenesis (Scanlan et al, 1994;
Wesley et al, 1999). In contrast, immunohistologic studies have de-
monstrated a highly selective FAP expression in stromal ¢bro-
blasts of over 90% of common human epithelial cancers (Garin-
Chesa et al, 1990), in the granulation tissue of healing wounds,
and in a large proportion of bone and soft tissue sarcomas (Rettig
et al, 1988). FAP is not expressed in epithelial tumor cells, and is
also not detectable in stromal ¢broblasts of benign epithelial
tumors, or normal adult tissues. The restricted distribution of
FAP in normal tissues and benign epithelial tumors in contrast
to its abundant expression in the stroma of a large proportion
of epithelial cancers has provided the rationale for immunother-
apy strategies aimed at the tumor stroma rather than surface
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molecules of malignant cells (Rettig et al, 1993). Recently it was
shown that FAP has both dipeptidyl peptidase and a collagenoly-
tic activity capable of degrading gelatin and type I collagen (Park
et al, 1999). In this study it was concluded that (i) FAP belongs to
the serine protease family rather than the matrix metalloprotease
family and (ii) cleavage of gelatin and native collagen I places
FAP into the group of enzymes possibly involved in tumor tissue
remodeling by a¡ecting extracellular matrix degradation and/or
growth factor activation.
Malignant melanoma is among the most aggressive tumors in
humans with minimal progress in nonsurgical treatment of ad-
vanced disease (Byers and Bhawan, 1998; McMasters et al, 1999).
In contrast to the more frequently occurring basal cell and squa-
mous cell carcinoma malignant melanoma is the most common
fatal malignancy among young adult Caucasians, and its
incidence and mortality continue to increase at an alarming rate
(Halachmi and Gilchrest, 2001). Although substantial progress has
been made in understanding the genetic changes and molecular
processes resulting in transformation of benign melanocytic nevi
to malignant melanomas (Chin et al, 1998; Ruiter et al, 2002), fun-
damental mechanisms of tumor cell invasion and metastasis of
primary melanomas remain unknown to date. Expression pro¢l-
ing studies using microarrays have revealed that growth factors,
cell adhesion molecules, proteases, and molecules involved in
intracellular signal transduction are di¡erentially expressed in
metastatic melanoma cells, suggesting important roles for mela-
noma progression (Bittner et al, 2000; Clark et al, 2000). FAP
may play an important role during melanoma progression, as
cultured normal melanocytes express FAP/DPP-IV, whereas ma-
lignant melanoma cell lines are FAP/DPP-IV negative or express
only FAP in culture (Rettig et al, 1993). Furthermore, in an in vitro
model of melanoma pathogenesis, v-Ha-ras transformation of
normal cultured melanocytes leads to partial growth factor inde-
pendence and ^ together with a fully transformed phenotype
(Houghton et al, 1988; Albino et al, 1992) ^ to successive stages of
FAP loss (Rettig et al, 1993). Although most molecular studies in
general originally focused on melanoma cells, it has become in-
creasingly evident that stromal cells, in particular ¢broblasts, play
key roles in processes of melanoma growth and metastasis, in-
cluding proliferation, matrix degradation, and migration (Liotta
et al, 1991; Fidler, 1995; Ruiter et al, 2002). Nothing so far is known
about the in vivo expression pattern of FAP in melanocytic skin
lesions ^ both in the stroma as well as on tumor cells ^ during
melanoma initiation and progression.
Therefore, this study was designed to determine FAP expres-
sion in a series of benign and malignant melanocytic lesions in
vivo and to link the in vivo expression pattern with the known
biochemical function that may help to explain its role in tumor-
igenesis and stroma remodeling events during transformation
and tumor progression.
MATERIALS AND METHODS
Tissues This study was approved by vote no. 117/2001 of the Ethical
Committee of the University of Ulm. After individual informed written
consent was given according to the guidelines, tissues were obtained from
surgical specimens, embedded in OCT compound, quick-frozen by the
isopentane/liquid nitrogen method, and stored at ^801C. Cryostat sections
(5 mm) were cut, air-dried, and ¢xed in cold acetone. The avidin^biotin
complex immunoperoxidase staining procedure was carried out as
described below. Tumor diagnoses were established through routine
pathologic evaluation of para⁄n-embedded tissues in the Departments of
Dermatology at the University of Ulm and Armed Forces Hospital of
Ulm. For all immunohistochemical assays, parallel sections were stained
with hematoxylineosin for additional histologic evaluation.
Immunohistochemistry The avidin-biotin complex immunoper-
oxidase method was carried out as previously described (Garin-Chesa
et al, 1987; 1988). Brie£y, 5 mm thick sections were cut, mounted on
poly(L-lysin)-coated slides, air-dried, and ¢xed in cold acetone (41C, for
10 min). Sections were treated with 0.3% H2O2 for 3 min to block
endogenous peroxidase followed by blocking with normal horse serum
for 30 min at room temperature. Slides were incubated at 41C with
monoclonal antibodies F19 (raised against Fibroblast Activation Protein, as
described by Rettig et al, 1988) and H572 (anti-Endoglyx-1, as described by
Sanz-Moncasi et al, 1994), hybridoma culture supernatants, diluted 1: 20;
mouse antihuman CD31/PECAM-1 (Dako, Glostrup, Denmark, diluted
1:100); mouse anti-S100 protein (Sigma, St. Louis, MO, diluted 1:5000);
mouse antihuman CD1a (Pharmingen, San Diego, CA, diluted 1: 500);
mouse anti-gp100 (HMB45, Dako, diluted 1: 500); or unrelated mouse
IgG-negative control antibodies (1^5 mg per ml) for 12^18 h. Sections
were washed and incubated with biotinylated horse antimouse IgG
(1:100; Vector Laboratories, Burlingame, CA) for 30 min at room
temperature, followed by avidin^biotinhorseradish peroxidase
complex (1:100 dilution at a 1:1 ratio). The ¢nal reaction product was
visualized with the chromogen 3,30 -diaminobencidine. Sections were
counterstained with Harris’s hematoxylin.
Indirect immuno£uorescence and confocal microscopy
Coexpression of FAP, Endoglyx-1, and gp100 was studied in a subset of
the melanoma specimens. For this purpose, the sections were incubated
sequentially with the corresponding primary antibodies followed
by di¡erentially labeled secondary antibodies, using an indirect
immuno£uorescence method. Goat antimouse IgG conjugated with Alexa
488 (Molecular Probes, Eugene, OR) was used for FAP expression (green
£uorescence) followed by a goat antimouse IgG Alexa 546 (Molecular
Probes) conjugated antibody for Endoglyx-1 expression (red £uorescence).
FAP expression and gp100 colocalization was studied by sequential
incubation with F19/Cy2 conjugated goat antimouse followed by an anti-
gp100/Cy3 conjugated goat antimouse antibody (Jackson,West Grove, PA,
Dianova, Hamburg, Germany). Sections stained by these double
immuno£uorescence procedures were examined and photographed with a
Leica TCS spectral confocal microscope.
Preparation of membrane extracts and dipeptidyl peptidase
assays A quantitative assay for dipeptidyl peptidase activity was
performed using Ala-Pro-AFC as the substrate, as described previously
(Park et al, 1999). In brief, frozen samples of tumor tissues or normal skin
(stored at ^801C) were thawed on ice, diced with a scalpel, snap frozen in
liquid nitrogen, and pulverized with a mortar and pestle. Extraction bu¡er
(150 mM NaCl, 50 mM TrisHCl bu¡er, pH 7.4, 10 mM MgCl2, 1%
Triton X-114) was added, and the resulting slurry was homogenized with
an Ultorax homogenizer for about 1 min and subsequently placed on ice
for 20 min. Extracts were cleared by centrifugation (4000 g) for 10 min
at 41C and phase-partitioned at 371C for 10^20 min, followed by
centrifugation (4000 g, 20 min at room temperature), without braking.
The detergent phase was diluted with 150 mM NaCl, 50 mM TrisHCl
bu¡er, pH 7.5, 5 mM CaCl2, 5 mM MgCl2, and 0.75% Empigen BB, and
separated on concanavalin A Sepharose. Concanavalin-A-bound fractions
were eluted with 1 M methyl-a-D-mannopyranoside, 150 mM NaCl,
50 mM TrisHCl bu¡er, pH 7.4, and 0.1% Empigen BB. Membrane
extracts were tested for FAP activity via an immunocapture step.
Enzyme-linked immunosorbent assay (ELISA) plates (96 well, Costar,
Corning, NY) were coated overnight at 41C with 1 mg per ml chimeric
F19 antibody or control antibody in phosphate-bu¡ered saline (PBS).
Wells were then rinsed with wash bu¡er (PBS, 0.1% Tween 20), and
excess binding sites were blocked with blocking bu¡er (5% bovine serum
albumin in PBS) for 1 h at room temperature. Blocking bu¡er was
removed; membrane extracts were added and incubated for 1 h at room
temperature. The unbound material was removed, wells were washed
thrice with wash bu¡er, and dipeptidyl peptidase activity was assayed
using 100 ml of Ala-Pro-AFC (0.5 mM Ala-Pro-AFC in reaction bu¡er)
for 1 h at 371C. Background £uorescence (as measured using control
antibody) was subtracted from each value. Release of free AFC was
measured in a Cyto£uor £uorimeter (PerSeptive Biosystems, Applied
Biosystems, Foster City, CA) using the 395 nm excitation/530 nm
emission ¢lter set.
RESULTS
FAP is induced in activated stromal ¢broblasts of
benign melanocytic nevi In order to determine FAP pro-
tein expression in melanocytic nevi we carried out an
immunohistochemical analysis of FAP distribution in nevi using
monoclonal antibody F19. Immunostaining demonstrated
positive staining of stromal ¢broblasts in all nevi (n¼19),
regardless of the histopathologic subtype (Fig 1,Table I). These
F19-positive stromal cells show a mesenchymal phenotype
and express various commonly used mesenchymal markers, such
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as vimentin and a-smooth muscle actin (data not shown),
consistent with ¢broblasts and myo¢broblasts. In most cases,
normal skin in distant and close vicinity to the melanocytic
lesion was also available for analysis. Interestingly, stromal cells
in normal skin adjacent to the nevi were F19 negative, whereas
F19 expression was already detectable in areas of in£ammation
(data not shown) and in reactive mesenchyme directly
surrounding the lesions (Fig 1B, D, F). The induction of FAP in
activated stromal ¢broblasts of benign melanocytic lesions is in
contrast to the ¢ndings in benign and premalignant epithelial
tumors, which generally lack FAP-positive stromal cells
(Garin-Chesa et al, 1990).
FAP is expressed on melanocytic cells in a subset of
melanocytic nevi In a subset of the melanocytic nevi FAP
was not only detected on stromal ¢broblasts but also on subsets
of melanocytic cells present at the dermo-epidermal junction
(Fig 1D, F). In each case, the histopathologic diagnosis was
con¢rmed and di¡erent cell types were identi¢ed by thorough
morphologic evaluation of hematoxylineosin stained sections
of the lesions (Fig 1A, C, E). In addition, we observed
expression of HMB-45 in some of the FAP-expressing nevus
cells, and expression of S100 protein in most of the FAP-positive
nevus cells in adjacent sections, respectively (see Materials
and Methods, data not shown). Of all cases studied (n¼19), we
found F19-positive melanocytic cells in approximately one-third
of all nevi (n¼ 6), regardless of the histopathologic subtype (see
Table I). This is again in contrast to the ¢ndings in benign and
malignant epithelial tumors that generally lack FAP expression
on the surface of epithelial tumor cells (Rettig et al, 1993).
FAP expression is induced in stromal ¢broblasts of
malignant melanomas and melanoma metastases In order
to determine the pattern of FAP expression in activated stromal
¢broblasts during transformation of benign melanocytic nevi to
malignant melanomas, a series of primary cutaneous melanomas
(n¼ 6), melanoma metastases (n¼12), and two cases of lentigo
maligna were investigated. The primary melanomas comprised
the following histopathologic subtypes: super¢cial spreading
(n¼ 2), nodular (n¼1), acrolentiginous (n¼1), and lentigo
maligna melanoma (n¼1) (Table I). In addition, one case of an
in situ melanoma was stained for FAP expression. FAP expression
was seen in activated stromal ¢broblasts in all cases (Table I;
Figs 2, 3). There was no signi¢cant di¡erence in the FAP
expression between primary and metastatic melanomas. In all
Figure1. Immunohistochemical detection of FAP in melanocytic
nevi with monoclonal antibody F19. Melanocytic nevi (A^F) were
stained either with hematoxylin-eosin (A, C, E), or with monoclonal anti-
body F19 to detect FAP expression (B, D, F). FAP immunoreactivity was
seen in the reactive stromal ¢broblasts surrounding the nevi (arrows; B, D,
F), but also on subsets of melanocytic cells at the dermo-epidermal junc-
tion (arrowheads; D, F) in compound nevi (C, E). Scale bar: 50 mm.




Tumor type n þ þ þ ^ Melanocytic/melanoma cells
Melanocytic nevus
Compound 13 13 4
Congenital 3 3 1
Dermal 1 1 ^
Dysplastic 2 2 1
In situ/primary melanoma
In-situ MM 1 1 ^
LM 2 2 ^
SSM 2 2 ^
NMM 1 1 ^
ALM 1 1 ^




Acetone-¢xed frozen sections were tested by the avidinbiotin complex im-
munoperoxidase procedure and results are indicated as follows: þ þ , þ , abun-
dant and moderate numbers of F19-positive stromal ¢broblasts, respectively; ,
antigen-negative; MM, malignant melanoma; LM, lentigo maligna; SSM, super-
¢cial spreading melanoma; NMM, nodular malignant melanoma; ALM, acrolen-
tiginous melanoma; LMM, lentigo maligna melanoma.
a12 samples obtained from seven di¡erent patients.
Figure 2. Immunohistochemical detection of FAP in primary mel-
anomas with monoclonal antibody F19. Primary melanomas (A^D)
were stained either with hematoxylin-eosin (A), or with monoclonal
antibody F19 to detect FAP expression (B^D). FAP immunoreactivity was
detected in stromal ¢broblasts around the melanoma cell clusters (arrows).
Scale bar: 50 mm.
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cases, hematoxylin^eosin staining was performed for
histolopathologic evaluation (Figs 2A^3A). The upregulation
of FAP in stromal ¢broblasts of melanocytic malignancies
resembles the ¢ndings in most epithelial cancers and supports
the hypothesis that this protease plays an important role in the
proliferative program of ¢broblastic cells. In contrast to the
melanocytic nevi, none of the malignant melanocytic tumors
tested express FAP on the melanoma cells themselves (Figs 2B^
D^3C, E, G).
FAP expression in stromal patterns of cutaneous melanoma
metastases In hematoxylineosin stainings of cutaneous
melanoma metastases, generally only a limited number of blood
vessels (resulting from tumor angiogenesis) is found (Fig 3A).
Conventional blood vessels are lined by endothelial cells, which
can be de¢ned by a panel of monoclonal antibodies against
endothelial cell surface proteins. Besides the commonly used
endothelial marker CD31, the highly endothelial lineage-speci¢c
cell surface glycoprotein Endoglyx-1 (Sanz-Moncasi et al, 1994;
Christian et al, 2001) was used as a marker for identi¢cation of
endothelial cells in cutaneous melanoma metastases by
immunohistochemical staining with monoclonal antibody H572
against Endoglyx-1 (Fig 3B). F19 and H572 immunostainings of
corresponding sections of metastatic melanomas demonstrate
clearly that tumor blood vessels are FAP negative (Fig 3C, E, G)
but show positive immunoreactivity for Endoglyx-1 (Fig 3B, D,
F, H). In each case, immunostaining for an additional endothelial
cell surface marker, CD31, was carried out and showed
immunoreactivity of the Endoglyx-1-positive structures (data
not shown). Surprisingly, we observed dense networks of
interconnected FAP-positive structures (loops, septa, and
channels) in a subset (n¼ 6) of the F19-stained metastatic
melanomas (n¼12; Fig 3C, E, G) that do not show Endoglyx-1
immunoreactivity in adjacent serial sections (Fig 3D, F, H). As
the characteristics of these structures were unclear, we next
focused on the further analysis of the FAP-expressing cells
constituting these patterned structures. For this purpose, double
immuno£uorescence experiments with anti-FAP and anti-
Endoglyx-1 were performed in sections of metastatic melanomas
and the results were evaluated by confocal microscopy. As
illustrated in Fig 4A^C, there was clearly no overlap between
the F19-positive structures (green £uorescence) and the H572-
positive tumor blood vessels (red £uorescence). In some sections,
however, the network of F19-positive structures appears to have
close contact to the vascular endothelium (Fig 4A). As the FAP-
expressing cells lining the observed structures could not be
identi¢ed as vascular endothelial cells, we asked whether these
FAP-positive structures may be related to the recently described
and possibly tumor-cell-generated vascular channels found in
aggressive uvea or metastatic human melanomas (Maniotis et al,
1999). Immunohistochemistry of adjacent serial sections from the
samples shown in Figs 3 and 4 were then stained for expression of
melanoma antigens. Colocalization of FAP and the melanoma
marker gp100 was studied by sequential incubation of metastatic
melanoma sections with F19 (green £uorescence) followed by
anti-gp100/HMB45 (red £uorescence). Confocal microscopy
showed no overlap between the FAP-positive cells constituting
interconnected channel- or loop-like patterns (Fig 4D^F; green
£uorescence) and the gp100-positive melanoma cells (Fig 4D^F;
red £uorescence) that are clustered around these septa.
Intriguingly, cutaneous metastases excised 3^5 mo later from the
same patients who were tested positive for this stromal feature
(n¼ 3) revealed the same FAP-positive structures that were
consistently negative for endothelial (CD31, Endoglyx-1) and
melanoma (gp100, S100) cell markers (data not shown). Based on
these expression data it is tempting to speculate that FAP may
constitute a previously unrecognized marker for speci¢c stromal
patterns found in a subset of metastatic melanomas.
Enzymatic FAP activity in melanocytic nevi and melanoma
metastases Given the fact that FAP protein expression is
detectable in the stroma of melanocytic nevi and following
transformation to malignant melanomas we next asked if FAP is
present as an active cell-surface-bound protease in the stroma of
melanocytic tumors. Recently, suitable test substrates for FAP
enzyme function, such as Ala-Pro-AFC, have been identi¢ed
(Park et al, 1999), and by establishing a FAP-speci¢c enzyme
immunocapture assay (Park et al, 1999) it has become feasible to
monitor FAP activity directly in samples of human tumor
tissues. Equal amounts of specimens of normal skin,
melanocytic nevi, and melanoma metastases were extracted and
subjected to enzyme immunocapture on monoclonal antibody
F19-coated ELISA plates. Bound dipeptidyl peptidase activity
measured with Ala-Pro-AFC as substrate showed a distinctive
pattern, as indicated in Fig 5. FAP activity could be detected in
extracts of all four melanocytic nevi and appears to be
upregulated in melanoma metastases (n¼ 6), whereas little or no
activity was detectable in biopsy specimens of normal skin
(n¼ 5), correlating well with results from immunohistochemical
staining.We conclude from these results that FAP is expressed as
an active protease in benign melanocytic skin tumors and its
increase in enzyme activity correlates with increased protein
expression following transformation to malignant melanomas.
Figure 3. Immunohistochemical detection of FAP and Endoglyx-1
in metastatic melanomas. Melanoma metastases (A^H) were stained
with hematoxylin-eosin (A), with monoclonal antibody F19 (C, E, G), or
with monoclonal antibody H572 to detect the endothelial-speci¢c Endo-
glyx-1 protein (B, D, F, H). Immunostainings of adjacent serial sections (C/
D, E/F, G/H) demonstrate that conventional tumor blood vessels (bv) are
Endoglyx-1 positive (D, F, H) and FAP negative (C, E, G). Note the net-
works of FAP-positive (Endoglyx-1-negative) loops and channels observed
in a subset of metastatic melanomas (C, E, G). Scale bar: 50 mm.
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DISCUSSION
With these studies we have for the ¢rst time systematically deter-
mined the expression pattern and enzymatic activity of FAP in a
series of melanocytic lesions ranging from benign melanocytic
nevi to metastatic melanoma. FAP protein is expressed in stromal
¢broblasts of all melanocytic tumors, including benign, prema-
lignant, and malignant lesions. The observed upregulation of
FAP expression and enzymatic activity during malignant trans-
formation from benign melanocytic nevi to malignant melano-
ma is consistent with its upregulation in more than 90% of all
investigated malignant epithelial tumors (including breast, color-
ectal, ovarian, lung, and pancreatic carcinomas; Garin-Chesa et al,
1990; Scanlan et al, 1994). In contrast to the ¢ndings in benign
epithelial tumors, however, in which no or very little expression
of FAP was observed on stromal ¢broblasts (Garin-Chesa et al,
1990), we detected considerable expression and enzymatic activity
of FAP in stromal ¢broblasts of benign melanocytic skin tumors.
The presence of FAP expression and activity in stromal ¢bro-
blasts of melanocytic nevi either suggests that FAP expression
does not perfectly correlate with the activation state of stromal
¢broblasts in melanocytic tumors, or emphasizes the fact that
melanocytic nevi can be considered as precursor lesions for mela-
noma development (Clark et al, 1984; Elder et al, 1989), character-
ized by an ^ at least partially ^ constitutively active tumor stroma.
Little is known about the molecular changes that accompany
activation of stromal ¢broblasts during tumor progression, and
gene expression pro¢ling studies would be highly informative
to address this question. The molecular response of resting ¢bro-
blasts to serum in vitro has been described using microarrays (Iyer
et al, 1999), but provides only a ¢rst approximation of possible
gene expression changes associated with the activation of stromal
¢broblasts during tumorigenesis. FAP appears to constitute an
ideal marker for expression pro¢ling of stromal ¢broblasts at dif-
ferent stages of melanoma progression, as a ¢rst step to identify
regulatory pathways in these cells linked to tumorigenesis. FAP is
detectable as an active serine protease in the reactive tumor stro-
ma of melanocytic skin tumors, showing a close correlation be-
tween the presence of immunohistochemically detectable FAP
and its dipeptidyl peptidase activity. The identi¢cation of key
substrates of FAP may provide an additional entry point in un-
derstanding the pathways that control the activation of stromal
¢broblasts during tumorigenesis.
FAP in addition may play a distinct role in the regulation of
growth and transformation programs of melanocytic cells. This
hypothesis is based on our observation that FAP expression in
melanocytic skin tumors was also detected on the surface of mel-
anocytes in 30% of melanocytic nevi assayed. A signi¢cantly lar-
ger number of nevi will need to be assayed for FAP expression, in
order to link expression in nevi with clinical melanoma progres-
sion and prognosis. In contrast, FAP expression was not found on
melanoma cells from primary and metastatic melanomas, consis-
tent with previous observations obtained in in vitro melanoma
models (Rettig et al, 1993). The role of FAP on melanocytic nevus
Figure 4. FAP expression on patterned structures does not overlap
with endothelial and melanoma cell markers. Sections from meta-
static melanoma lesions were examined under a confocal microscope
for colocalization of FAP with endothelial markers. Double stainings were
carried out with monoclonal antibody F19 detected by Alexa-488-conju-
gated secondary antibody (green £uorescence, A^C) and with monoclonal
antibody H572 detected byAlexa-546-conjugated secondary antibody (red
£uorescence, A^C) staining endothelial cells of blood vessels (bv). Mono-
clonal antibody F19 detected with Cy2-conjugated secondary antibody
(green £uorescence, D^F) and anti-gp100/HMB45 detected with Cy3-con-
jugated antibody (red £uorescence, D^F) were used for colocalization of
FAP and the melanoma marker gp100 staining melanoma cells (mc). Color
overlay analysis demonstrates no colocalization of FAP with Endoglyx-1
(A^C) or with gp100 (D^F). Scale bar: 50 mm.
Figure 5. Dipeptidyl peptidase activity of FAP measured in extracts
of human melanoma metastases (blue symbols), melanocytic nevi
(red symbols), and matched normal skin (open symbols).Melanoma
samples included three specimens from one individual (circles) and two spe-
cimens from another patient (triangles); all other samples in this ¢gure
(squares) were from di¡erent patients. FAP activity was measured using
concanavalin-A-enriched membrane fractions, followed by binding to
F19-coated plates and incubation with Ala-Pro-AFC as substrate. The bars
and respective numbers represent the mean of each category. The di¡er-
ences between the means for melanoma metastases and melanocytic nevi
versus normal skin, respectively, are signi¢cant at po10^4 by Student’s t test.
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cells, as well as its downregulation on melanoma cells ^ which is
in contrast to many other proteases, including matrix metallopro-
teinases and uPA (Hofmann et al, 2000; Ruiter et al, 2002) ^ is
currently not understood. Further insight into the role of FAP
on melanoma versus stromal cells may be provided by further dis-
section of growth and/or di¡erentiation signals leading to the ac-
tivation of FAP in di¡erent cell types, such as transforming
growth factor b or retinoic acid, as previously suggested (Rettig
et al, 1994). In melanoma cells, FAP appears to form heterodimers
with the related protease DPP-IV/CD26, which is also downre-
gulated in the in vitro models previously analyzed (Rettig
et al, 1993).Wesley et al (1999) reported that reexpression of DPP-
IV/CD26 in melanoma cells at levels expressed by normal
melanocytes leads to a loss of tumorigenicity and change in
phenotype that is characteristic of normal melanocytes.
Further functional studies will be required to determine whether
FAP and DPP-IV/CD26 have similar or even partially redundant
functions in cell survival and transformation of melanocytes.
Interestingly, we observed strong protein expression of FAP in
patterned structures in a subset of the melanoma metastases ana-
lyzed in this study. As the FAP-positive networks described in
this report are negative for endothelial as well as melanoma cell
surface markers, but appear to have close contact to tumor blood
vessels, we propose that they are most probably derived from
stromal ¢broblasts. Several studies have previously identi¢ed pat-
terned structures in the melanoma stroma. In uveal melanoma,
using a modi¢cation of the periodic acidSchi¡ reaction,
Folberg et al (1992) identi¢ed so-called ‘‘vascular patterns’’, some
of which were associated with an unfavorable prognosis. Based
on more recent studies (Foss et al, 1997; Clarijs et al, 2002), the
current opinion is that the ‘‘vascular patterns’’ in uveal melanoma
represent ¢brovascular stromal septa, but not microvessels
expressing endothelial markers (Ruiter et al, 2002). Several groups
(McDonald et al, 2000; Clarijs et al, 2002) were unable to detect
the ‘‘vascular channels’’ described by Maniotis et al (1999) as ery-
throcyte-¢lled spaces lined by melanoma cells communicating
directly with endothelium-lined microvessels. Instead, they sug-
gested that the ¢brovascular septa may act as an extracellular
matrix meshwork that provides a medium for di¡usion of soluble
factors. Recently,Warso et al (2001) identi¢ed ¢brovascular stro-
mal patterns in primary cutaneous melanoma that resembled
those observed in uvea melanoma. Architectural variations in
and around cutaneous melanoma appear to include several pat-
terns, such as nodular, micronodular or nested, mixed nodular/
micronodular, and desmoplastic, several of which form typical
‘‘loop’’ and ‘‘network’’ structures (Banerjee and Harris, 2000;
Ruiter et al, 2002).
Ultimately, to pinpoint the importance of FAP for melanoma
onset and/or progression, we may have to await the results of
mouse tumor models or, more likely, studies with highly selective
inhibitors of FAP. Stromal therapy is increasingly viewed as an
attractive approach to cancer prevention and intervention (Liotta
and Kohn, 2001). Selective ablation of FAP-positive stromal ¢bro-
blasts will constitute a promising approach to demonstrate the
contribution of stromal ¢broblasts to melanocytic skin tumors.
In summary, FAP expression appears to be a highly speci¢c mar-
ker for reactive tumor stromal ¢broblasts of human epithelial
cancers and, as demonstrated in this report, of melanocytic skin
tumors. It remains to be seen whether stromal expression of FAP
in highly patterned structures found in melanoma metastases will
correlate with a poor prognosis.
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